Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
Treatment pattern and outcomes in patients with uncommon or compound EGFR mutations in India: CRSF 2020-03 study. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...
Current treatment guidelines recommend that mNSCLC patients should be tested for actionable mutations to help guide appropriate first-line treatment options. 7 “In patients with mNSCLC of ...
J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
In a recent study published in Micromachines, researchers assessed the efficiency of a genetic decoding system for diagnosing non-small cell lung cancer (NSCLC). Study: Intelligent Genetic Decoding ...
WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback